Acute heart failure (AHF) is characterized by the rapid onset or aggravation of symptoms of heart failure. The standard of care in AHF has remained largely unchanged since the 1970s, resulting in a highly genericized market. AHF patients continue to experience high rates of mortality and morbidity because no therapy to date has been able to improve hard clinical outcomes. This study evaluates how current therapies are differentiated based on their performance on key drug attributes and measures the impact of these attributes on the prescribing behavior of cardiologists. Revealing the relative importance of unmet needs helps identify the most attractive opportunities in AHF treatment.
QUESTIONS ANSWERED
Which drug attributes most strongly influence AHF drug selection?
How do cardiologists rate key current AHF therapies across select drug attributes?
Where are the hidden opportunities for drug development in the AHF therapy market?
Do U.S. and European cardiologists have different perceptions of the unmet need in the treatment of AHF?
PRODUCT DESCRIPTION
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
Markets covered: United States, United Kingdom, France, Germany.
Primary research: Survey of 60 U.S. and 32 European cardiologists fielded in December 2019.
Key companies: Novartis, Johnson & Johnson, Pfizer.
Unmet Need - Acute Heart Failure - Executive Summary - February 2020
Introduction
Overview
Methodology
Rationale for Treatment Drivers and Goals Selection
Rationale for Drug Selection
Products for Acute Heart Failure and Rationale for Drug Selection
Treatment Drivers and Goals
Key Findings: Attribute Importance
Relative Importance of Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Surveyed Cardiologists' Prescribing Decisions in Acute Heart Failure
Importance of Efficacy Attributes to Prescribing Decisions in Acute Heart Failure: United States
Importance of Efficacy Attributes to Prescribing Decisions in Acute Heart Failure: Europe
Importance of Safety and Tolerability Attributes to Prescribing Decisions in Acute Heart Failure: United States
Importance of Safety and Tolerability Attributes to Prescribing Decisions in Acute Heart Failure: Europe
Key Findings: Stated vs. Derived Importance
Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Acute Heart Failure: United States
Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Acute Heart Failure: Europe
Product Performance Against Treatment Drivers and Goals
Key Findings
Overall Performance of Key Therapies for Acute Heart Failure: United States
Overall Performance of Key Therapies for Acute Heart Failure: Europe
Mean Overall Performance of Key Therapies for Acute Heart Failure: United States and Europe
Relative Performance of Key Therapies for Acute Heart Failure Across Select Efficacy Attributes: United States
Relative Performance of Key Therapies for Acute Heart Failure Across Select Efficacy Attributes: Europe
Relative Performance of Key Therapies for Acute Heart Failure Across Select Safety and Tolerability Attributes: United States
Relative Performance of Key Therapies for Acute Heart Failure Across Select Safety and Tolerability Attributes: Europe
Assessment of Unmet Need
Key Findings: Unmet Need in Acute Heart Failure
Surveyed Cardiologistsu2019 Satisfaction with the Performance of Key Therapies for Acute Heart Failure on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: United States
Surveyed Cardiologistsu2019 Satisfaction with the Performance of Key Therapies for Acute Heart Failure on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: Europe
Surveyed Cardiologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Acute Heart Failure: United States
Surveyed Cardiologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Acute Heart Failure: Europe
Surveyed Cardiologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Acute Heart Failure: United States
Surveyed Cardiologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Acute Heart Failure: Europe
Key Findings: Unmet Need in Acute Heart Failure and Related Indications
Surveyed Cardiologists' Ascribed Level of Unmet Need in Acute Heart Failure and Related Indications: United States
Surveyed Cardiologists' Ascribed Level of Unmet Need in Acute Heart Failure and Related Indications: Europe
Opportunity Analysis
Areas of Opportunity in the Acute Heart Failure Market and Emerging Therapy Insights
Opportunity: A Novel Agent That Significantly Reduces the Rate of Cardiovascular Mortality in Acute Heart Failure
Opportunity: A Novel Agent That Reduces the Rate of Rehospitalization for Heart Failure
Opportunity: A Novel Agent That Shows Significant Improvement in the Incidence of Worsening Heart Failure and Reduces the Length of Hospital Stay
Target Product Profiles
Assessing Drug Development Opportunities
Target Product Profile Methodology
Attributes and Attribute Levels
Attributes of Key Current and Late-Phase Emerging Therapies for Acute Heart Failure
Rate of Rehospitalization for Worsening Renal Function
Price Per Treatment Cycle
Conjoint Analysis-Based Simulation of a Market Scenario
Acute Heart Failure Market Simulation: Share of Preference of Target Product Profiles Included in the Market Scenario
Acute Heart Failure Market Simulation: Likelihood to Prescribe Target Product Profiles Included in the Market Scenario
Acute Heart Failure Market Simulation: Target Product Profiles Included in the Market Scenario
Appendix
Key Abbreviations
Bibliography
Dwaipayan Chatterjee, M.Pharm.
Dwaipayan Chatterjee, M.Pharm., is an analyst on the Cardiovascular, Metabolic, Renal, and Hematologic (CMRH) Disorders team at Clarivate. He has authored reports focusing on metabolic and cardiovascular indications. Previously, he was an equity analyst for the U.S. healthcare sector with Market Realist, where he worked on competitive intelligence and analysis of financial data. He was also a market research analyst for Mordor Intelligence, where he gained experience in market sizing, forecasting, and analyzing market dynamics. He holds a master’s degree with a specialization in pharmaceutical chemistry from the Birla Institute of Technology & Science in Pilani, India.